← FDA DRUG APPROVALS

FDA ANDA · ANDA205775

EVEROLIMUS

Sponsor: PH HEALTH

APPLICATION
ANDA205775
TYPE
ANDA
ORIGINAL APPROVAL
2021-10-18
LATEST ACTION
2021-10-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

EVEROLIMUSPrescription
EVEROLIMUS 0.75MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 0.25MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 1MG · TABLET · ORAL
EVEROLIMUSPrescription
EVEROLIMUS 0.5MG · TABLET · ORAL

Approval history

2021-10-18UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →